Bristol-Myers Squibb Co. will receive more than $480 million from a collaboration agreement with British consumer goods company Reckitt Benckiser Group PLC over the sale of several over-the-counter drugs mostly in Mexico and Brazil.
The New York drug developer said Tuesday Reckitt Benckiser will pay $438 million upfront for exclusive rights to sell products like the antacid Picot, the pain reliever Tempra and the cold-and-cough medicine Graneodin over three years. Reckitt Benckiser will buy the products from Bristol and pay royalties during the collaboration.
The British company also will pay an option fee of $44 million for the right to buy the products outright at the end of the three-year agreement. That includes acquiring sales and distribution rights, trademarks, inventories and other assets. The purchase price then will be based on average sales during a two-year period before the deal closes.
Bristol-Myers Squibb shares finished at $36.93 on Monday.